Soluble CD163 as a Non-Invasive Biomarker in Autoimmune Nephrological and Rheumatological Diseases
References
- Ambarus CA, Noordenbos T, de Hair MJ et al. (2012) Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. Arthritis Res Ther 14:R74.
https://doi.org/10.1186/ar3796 - Arazi A, Rao DA, Berthier CC et al. (2019) The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol 20:902–914.
https://doi.org/10.1038/s41590-019-0398-x - Arias de la Rosa I, López-Montilla MD, Román-Rodríguez C et al. (2022) The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast. J Intern Med 291:676–693.
https://doi.org/10.1111/joim.13447 - Baeten D, Møller HJ, Delanghe J et al. (2004) Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 50:1611–1623.
https://doi.org/10.1002/art.20174 - Brown AK, Quinn MA, Karim Z et al. (2006) Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 54:3761–3773.
https://doi.org/10.1002/art.22190 - Chen S, Saeed AFUH, Liu Q et al. (2023) Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther 8:207.
https://doi.org/10.1038/s41392-023-01452-1 - Do T, Tan R, Bennett M et al. (2018) MicroRNA networks associated with active systemic juvenile idiopathic arthritis regulate CD163 expression and anti-inflammatory functions in macrophages through two distinct mechanisms. J Leukoc Biol 103:71–85.
https://doi.org/10.1002/JLB.2A0317-107R - Endo N, Tsuboi N, Furuhashi K et al. (2016) Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. Nephrol Dial Transplant 31:2023–2033.
https://doi.org/10.1093/ndt/gfw214 - Etzerodt A, Moestrup SK (2013) CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal 18:2352–2363.
https://doi.org/10.1089/ars.2012.4834 - Fonseca JE, Edwards JC, Blades S et al. (2002) Macrophage subpopulations in rheumatoid synovium: reduced CD163 expression in CD4+ T lymphocyte-rich microenvironments. Arthritis Rheum 46:1210–1216.
https://doi.org/10.1002/art.10207 - Gloor AD, Yerly D, Adler S et al. (2018) Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis. Rheumatology 57:1795–1801.
https://doi.org/10.1093/rheumatology/key158 - Gong S, Jin S, Li Y et al. (2021) Urinary soluble CD163 levels predict IgA nephropathy remission status. Front Immunol 12:769802.
https://doi.org/10.3389/fimmu.2021.769802 - Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32:593–604.
https://doi.org/10.1016/j.immuni.2010.05.007 - Greisen SR, Moller HJ, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Jørgensen A, Hvid M, Deleuran B. Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis. Clin Exp Rheumatol. 2011 Jul–Aug;29(4):689–92. Epub 2011 Sep 1. PMID: 21813065.
- Greisen SR, Møller HJ, Stengaard-Pedersen K Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Deleuran B. et al. (2015) Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs. Clin Exp Rheumatol 2015 Jul–Aug;33(4):498–502. Epub 2015 May 11. PMID: 25962601.
- Gupta R, Yadav A, Aggarwal A (2021) Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis. Clin Rheumatol 40:941–948.
https://doi.org/10.1007/s10067-020-05343-6 - Heftdal LD, Loft AG, Hendricks O et al. (2018) Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis. Scand J Clin Lab Invest 78:483–489.
https://doi.org/10.1080/00365513.2018.1500704 - Huang YJ, Lin CH, Yang HY et al. (2022) Urine aoluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis. Front Immunol 13:935700.
https://doi.org/10.3389/fimmu.2022.935700 - Jude C, Dejica D, Samasca G et al. (2013) Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis. Rheumatol Int 33:1031–1037.
https://doi.org/10.1007/s00296-012-2459-4 - Kinne RW, Stuhlmüller B, Burmester GR (2007) Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther 9:224.
https://doi.org/10.1186/ar2333 - Kristiansen M, Graversen JH, Jacobsen C et al. (2001) Identification of the haemoglobin scavenger receptor. Nature 409:198–201.
https://doi.org/10.1038/35051594 - Kurasawa S, Kato S, Ozeki T (2024) Rationale and design of the Japanese Biomarkers in Nephrotic Syndrome (J-MARINE) study. Clin Exp Nephrol 28:431–439.
https://doi.org/10.1007/s10157-023-02449-4 - Li J, Lv J, Wong MG et al. (2024) Correlation of urinary soluble CD163 levels with disease activity and treatment response in IgA nephropathy. Kidney Int Rep 9:3016–3026.
https://doi.org/10.1016/j.ekir.2024.07.031 - Malvar A, Pirruccio P, Alberton V et al. (2017) Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 32:1338–1344.
https://doi.org/10.1093/ndt/gfv296 - Mantovani A, Sica A, Sozzani S et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677–686.
https://doi.org/10.1016/j.it.2004.09.015 - Matsushita N, Kashiwagi M, Wait R et al. (2002) Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 130:156–161.
https://doi.org/10.1046/j.1365-2249.2002.01963.x - Mejia-Vilet JM, Zhang XL, Cruz C et al. (2020) Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis. J Am Soc Nephrol 31:1335–1347.
https://doi.org/10.1681/ASN.2019121285 - Mills CD, Kincaid K, Alt JM et al. (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164:6166–6173.
https://doi.org/10.4049/jimmunol.164.12.6166 - Møller HJ (2012) Soluble CD163. Scand J Clin Lab Invest 72:1–13.
https://doi.org/10.3109/00365513.2011.626868 - Moran SM, Scott J, Clarkson MR et al. (2021) The clinical application of urine soluble CD163 in ANCA-associated vasculitis. J Am Soc Nephrol 32:2920–2932.
https://doi.org/10.1681/ASN.2021030382 - Murray PJ, Allen JE, Biswas SK et al. (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14–20.
https://doi.org/10.1016/j.immuni.2014.06.008 - Nielsen AJ, Nielsen MC, Birn H et al. (2020) Urine soluble CD163 (sCD163) as biomarker in glomerulonephritis: stability, reference interval and diagnostic performance. Clin Chem Lab Med 59:701–709.
https://doi.org/10.1515/cclm-2020-0466 - Nikolic-Paterson DJ, Atkins RC (2001) The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 16(Suppl. 5):3–7.
https://doi.org/10.1093/ndt/16.suppl_5.3 - Nishino A, Katsumata Y, Kawasumi H et al. (2019) Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus. Lupus 28:986–994.
https://doi.org/10.1177/0961203319860201 - O'Reilly VP, Wong L, Kennedy C et al. (2016) Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol 27:2906–2916.
https://doi.org/10.1681/ASN.2015050511 . Erratum in: J Am Soc Nephrol 2018 29:2255.https://doi.org/10.1681/ASN.2018060582 - Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111:1805–1812.
https://doi.org/10.1172/JCI18921 - Plevriti A, Lamprou M, Mourkogianni E et al. (2024) The role of soluble CD163 (sCD163) in human physiology and pathophysiology. Cells 13:1679.
https://doi.org/10.3390/cells13201679 - Renaudineau Y, Chauveau D, Faguer S et al. (2024) Urinary soluble CD163 is useful as “liquid biopsy” marker in lupus nephritis at both diagnosis and follow-up to predict impending flares. J Transl Autoimmun 9:100244.
https://doi.org/10.1016/j.jtauto.2024.100244 - Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795.
https://doi.org/10.1172/JCI59643 - Strizova Z, Benesova I, Bartolini R et al. (2023) M1/M2 macrophages and their overlaps - myth or reality? Clin Sci 137:1067–1093.
https://doi.org/10.1042/CS20220531 - Tan J, Cheng J, Yang X et al. (2026) CD163 at the crossroads: a viral-exploited immunomodulator. Virol J 23:44.
https://doi.org/10.1186/s12985-026-03082-9 - Vandooren B, Noordenbos T, Ambarus C et al. (2009) Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 60:966–975.
https://doi.org/10.1002/art.24406 - Villacorta J, Lucientes L, Goicoechea E et al. (2020) Urinary soluble CD163 as a biomarker of disease activity and relapse in antineutrophil cytoplasm antibody-associated glomerulonephritis. Clin Kidney J 14:212–219.
https://doi.org/10.1093/ckj/sfaa043 - Wynn TA, Vannella KM (2016) Macrophages in tissue repair, regeneration, and fibrosis. Immunity 44:450–462.
https://doi.org/10.1016/j.immuni.2016.02.015 - Xia T, Zhang M, Lei W et al. (2023) Advances in the role of STAT3 in macrophage polarization. Front Immunol 14:1160719.
https://doi.org/10.3389/fimmu.2023.1160719 - Yadav S, Dwivedi A, Tripathi A (2022) Biology of macrophage fate decision: implication in inflammatory disorders. Cell Biol Int 46:1539–1556.
https://doi.org/10.1002/cbin.11854 - Yang G, Guo N, Yin J et al. (2021) Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China. J Int Med Res 49:3000605211049963.
https://doi.org/10.1177/03000605211049963 - Zhang T, Li H, Vanarsa K et al. (2020) Association of urine sCD163 with proliferative lupus nephritis, fibrinoid necrosis, cellular crescents and intrarenal M2 macrophages. Front Immunol 11:671.
https://doi.org/10.3389/fimmu.2020.0067 .
DOI: https://doi.org/10.2478/aite-2026-0024 | Journal eISSN: 1661-4917
Language: English
Submitted on: Feb 28, 2026
Accepted on: Jun 18, 2026
Published on: Sep 1, 2026
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2026 Dorota Kamińska, Paweł Poznański, Wojciech Tański, Anna Skotny, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.